Diabetic Retinopathy Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceDeficiency associated with diabetic retinopathy severity
Supporting Studies (1)
Anti-inflammatory; supports retinal health
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsMacular pigments that protect retina; may be depleted in diabetes
Supporting Studies (1)
Antioxidant; studied for diabetic complications
Supporting Studies (1)
Fat-soluble vitamin B1; may protect against diabetic vascular damage
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Diabetic retinopathy is an eye complication of diabetes that damages the blood vessels in the retina. It's the leading cause of blindness in working-age adults.
STAGES:
DIABETIC MACULAR EDEMA:
RISK FACTORS:
CRITICAL: The most important treatment is blood sugar control and regular eye exams.
MEDICAL TREATMENTS:
SCREENING:
* Blood sugar control is the most effective prevention.
* Regular eye exams detect changes early.
* Supplements may support retinal health but don't replace medical care.
Expected timeline: Retinopathy develops over years. Supplements provide supportive benefit. Medical interventions prevent progression.
Clinical Perspective
Diabetic Retinopathy: Microvascular complication of diabetes; leading cause of blindness in working-age adults. Classification: nonproliferative (NPDR - mild, moderate, severe) and proliferative (PDR). Diabetic macular edema (DME) can occur at any stage.
Treatment: Glycemic control most important (reduces risk by 76% in DCCT). BP control. Anti-VEGF injections (ranibizumab, aflibercept, bevacizumab) first-line for center-involving DME. Laser for PDR and non-center-involving DME. Supplements: limited specific evidence; general antioxidant support may help. Does NOT replace blood sugar control and medical treatment.
* Vitamin D (C-grade): Association with severity. Systematic review: (PMID: 28750270). 2000-4000 IU daily.
* Omega-3 (C-grade): Retinal health. Review: (PMID: 27840029). 2-3g EPA+DHA daily.
* Lutein/Zeaxanthin (C-grade): Macular pigment. Review: (PMID: 23571649). 10mg/2mg daily.
* Alpha-Lipoic Acid (C-grade): Antioxidant. Review: (PMID: 17054254). 300-600mg daily.
* Benfotiamine (C-grade): Vascular protection. Trials: (PMID: 18282478). 300-600mg daily.
Protocol notes: Screening: dilated fundus exam annually; more frequently with retinopathy. A1c goal: <7% reduces microvascular complications. BP: <130/80 if tolerated. Lipids: statin for most diabetics. Anti-VEGF: transformative for DME; requires repeated injections. Laser: PRP for PDR; focal for some DME. Vitrectomy: non-clearing hemorrhage, tractional detachment. Pregnancy: retinopathy can worsen; exam before conception, each trimester. Fenofibrate: may reduce progression (ACCORD/FIELD). Prevention: tight glycemic control from diagnosis most effective strategy.